Earnings
Delcath Expects Sales To Fall Below $35.1 Million Quarter Despite Raising Annual Outlook
Management expects holiday schedules and fewer new patient starts to slow the fourth quarter, even as its treatment network expands.
Delcath Systems (DCTH) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Management expects holiday schedules and fewer new patient starts to slow the fourth quarter, even as its treatment network expands.
SEC Filings
The liver-cancer treatment company raised its 2026 sales outlook to $115 million–$117 million while spending more on trials and expansion.
SEC Filings
The filing reports 6,692,491 shares, or 9.9% of the class, and restates how two Rosalind principals joined Delcath's board.